US20200246054A1 - Surgical Method and Apparatus for Destruction and Removal of Intraperitoneal, Visceral, and Subcutaneous Fat - Google Patents

Surgical Method and Apparatus for Destruction and Removal of Intraperitoneal, Visceral, and Subcutaneous Fat Download PDF

Info

Publication number
US20200246054A1
US20200246054A1 US16/840,363 US202016840363A US2020246054A1 US 20200246054 A1 US20200246054 A1 US 20200246054A1 US 202016840363 A US202016840363 A US 202016840363A US 2020246054 A1 US2020246054 A1 US 2020246054A1
Authority
US
United States
Prior art keywords
cryoprobe
fat
intraperitoneal
vacuum sleeve
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US16/840,363
Other versions
US11844559B2 (en
Inventor
Ayad K. M. Agha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US16/840,363 priority Critical patent/US11844559B2/en
Publication of US20200246054A1 publication Critical patent/US20200246054A1/en
Application granted granted Critical
Publication of US11844559B2 publication Critical patent/US11844559B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A61M1/008
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00059Material properties
    • A61B2018/00089Thermal conductivity
    • A61B2018/00101Thermal conductivity low, i.e. thermally insulating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053Mechanical features of the instrument of device
    • A61B2018/00273Anchoring means for temporary attachment of a device to tissue
    • A61B2018/00291Anchoring means for temporary attachment of a device to tissue using suction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452Skin
    • A61B2018/00458Deeper parts of the skin, e.g. treatment of vascular disorders or port wine stains
    • A61B2018/00464Subcutaneous fat, e.g. liposuction, lipolysis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00577Ablation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • A61B2018/00815Temperature measured by a thermistor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636Sensing and controlling the application of energy
    • A61B2018/00773Sensed parameters
    • A61B2018/00791Temperature
    • A61B2018/00821Temperature measured by a thermocouple
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00982Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body combined with or comprising means for visual or photographic inspections inside the body, e.g. endoscopes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A61B2018/0231Characteristics of handpieces or probes
    • A61B2018/0262Characteristics of handpieces or probes using a circulating cryogenic fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2218/00Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2218/001Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body having means for irrigation and/or aspiration of substances to and/or from the surgical site
    • A61B2218/002Irrigation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2218/00Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2218/001Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body having means for irrigation and/or aspiration of substances to and/or from the surgical site
    • A61B2218/007Aspiration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08Detecting organic movements or changes, e.g. tumours, cysts, swellings
    • A61B8/0833Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
    • A61B8/0841Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures for locating instruments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/12Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/84Drainage tubes; Aspiration tips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/08Lipoids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/05General characteristics of the apparatus combined with other kinds of therapy

Definitions

  • This invention is directed to
  • Obesity in the United States is a major health issue, resulting in numerous diseases, specifically increased risk of certain types of cancer, coronary artery disease, type 2 diabetes, stroke, as well as significant economic costs.
  • Intraperitoneal fat is known to be difficult to remove by diet and exercise.
  • Cryosurgery is one method of killing tissue and is used for cancer treatments. It is a candidate for removal of intraperitoneal fat under the right conditions.
  • current methods and equipment is inadequate to avoid internal organ damage when organs are interspersed in the intraperitoneal fat. Internal organs are likely to be damaged from freezing fat tissue if there is no methodology to identify organ positions to ensure that no damage is created. Additionally, current cryosurgery methods do not address removal of frozen tissue during surgery.
  • U.S. Pat. No. 5,112,302 describes liposuction, which is used for removal of subcutaneous fat. The removal of fat is based on mechanical liquification of fat and then the fat is removed by vacuum. This motion of the cannula in the fat is very traumatic, and complications such as seromas, numbness, skin infections, or an internal puncture from the moving cannula can occur.
  • Cryosurgery is used in cancer treatment by utilizing liquid nitrogen or argon gas on cancerous tissue to destroy it.
  • the gas is used to cool a cryoprobe which in turn is used to freeze an internal tumor and surrounding tissue.
  • liquid nitrogen is sprayed directly to the cancer cells or swabbed onto the tumor with a cotton swab.
  • the embodied invention is a method of removing intraperitoneal fat by using a cryoprobe and inserting it into the abdominal cavity.
  • the cryoprobe is covered by a vacuum sleeve which provides for a method for intraperitoneal fat removal once the cells are damaged.
  • a multi-step surgical procedure is used to freeze, irrigate, and remove the destroyed fat tissue.
  • an ultrasonic transmitter is inserted into an outer cryoprobe sheath to assess organ position with the advantage of an internal transmitter which greatly aids in organ identification.
  • FIG. 1 shows a cross section of a cryogenic cryoprobe tip.
  • FIGS. 2A-2D show fat tissue in a horizontal cross section of a human abdomen, and placement of a cryoprobe.
  • FIG. 3A-3F show the end of cryoprobe and how it is used in surgery.
  • FIG. 3G-3K show the end of the cryoprobe and how it is used to create an ice ball of fat tissue, irrigate it, and remove it.
  • FIG. 4 shows how a cryogenic gas is connected to the cryoprobe.
  • FIG. 5 shows how the abdomen is dived for repetitive treatments.
  • FIG. 6 is a perspective view of the vacuum sleeve, illustrating the end holes.
  • cryoprobe When cryogenically treating cancer tumors inside the body, liquid nitrogen or argon flows through a hollow instrument called a cryoprobe, which is placed inside (or in contact with) the tumor to freeze it. Similarly, a cryoprobe can be used to freeze fat tissue.
  • a surgeon uses internal imaging equipment (ultrasound or MRI) to guide the cryoprobe to the correct location and monitor the freezing of the fat cells to avoid damage to nearby organs.
  • MRI magnetic resonance imaging equipment
  • the cryogen argon or nitrogen
  • a ball of frozen tissue forms around the cryoprobe, killing the cells.
  • the cryoprobe is put into the fat tissue through the skin (percutaneously).
  • the frozen tissue is then thawed and removed. Sometimes, more than one freeze-thaw cycle is be used.
  • FIG. 1 (not to scale) is a cross section of the cryoprobe.
  • the cryoprobe is typically 3-6 mm in diameter and the length 102 of the tip 103 is about 1.5 mm or so.
  • the exposed tube length 101 is about 3-6 cm long. These dimensions are not strict requirements.
  • the distal exposed section 101 of the cryoprobe is a cryocooler to reach the temperature needed to kill peritoneal fat cells. It is delineated by the insulation 107 along the length of the cryoprobe outer shaft.
  • the insulation is preferably an insulating plastic.
  • the uninsulated length 101 is a cryocooler and freezes fat tissue from the cryoprobe surface outward.
  • cryogen flow is stopped, and the tissue is allowed to thaw internally.
  • high pressure argon gas is used as the cryogen to cool the tip of the cryoprobe, it flows through a small diameter inner tube 105 , and expands at the end of the inner tube 106 .
  • the expanding Argon gas cools the cryoprobe to a very low temperature due to the Joule-Thompson effect.
  • the low pressure Argon gas is then routed through an exhaust chamber 104 to be vented away from the patient. No Argon gas is released inside the patient's body.
  • U.S. Pat. Nos. 7,479,139 and 7,846,154 are examples of cryoprobes.
  • high-pressure gas refers to gas pressures that will cause a Joule-Thomson cooling of cryoprobes to ⁇ 40° C. and lower.
  • “high-pressure” argon is typically between 3000 psi and 4500 psi, though somewhat higher and lower pressures may be used.
  • the working high pressure range is typically 1800-2500 psi.
  • cryosurgery can be confined to a small region of tissue, sparing the surrounding healthy tissue. The freezing process is precise and controlled, as the freezing interface in the fat tissue is sharp and propagates slowly from the tip.
  • a small cryoprobe having a diameter of around 4 mm can produce a 3.5 cm diameter frozen ellipsoid ball to treat a relatively large tissue region in a few minutes.
  • cryosurgery does not create a lot of complications and has low patient morbidity. Cryosurgery produces excellent therapeutic results with less distress at a lower cost. In addition, retreatment is possible.
  • FIG. 2A is a cross sectional image of abdominal fat tissue compartments. Fat tissues of specific areas are shown in cross hatching:
  • FIG. 2B shows a cryoprobe 204 inserted into the abdomen and creating an ice ball 205 of frozen intraperitoneal fat 203 .
  • FIG. 2C shows a cryoprobe 204 inserted into the abdomen and creating an ice ball 206 of frozen retro-intraperitoneal fat 207 .
  • FIG. 2D shows a cryoprobe and an ice ball 208 of frozen subcutaneous fat.
  • the Argon gas typically creates a cryoprobe end temperature of ⁇ 40° C. for freezing fat tissue. However, only a temperature of ⁇ 10° C. (or lower) is needed for cell destruction, and the cryoprobe end is alternately designed for less than ⁇ 10° C.
  • Argon gas (or other cryogen gas) is supplied by a high pressure cylinder 401 .
  • a shutoff valve 402 on top of the cylinder is connected to a supply line 403 which is connected to a cryoprobe control system 404 .
  • the control system provides temperature regulation by regulating the amount of Argon allowed to a cryoprobe supply line 405 .
  • the return gas from the cryoprobe is routed through a return line 406 and is ultimately vented 408 from the cryoprobe control system.
  • the control system includes needed piping and valve and automated computer control.
  • a computer interface 411 provides for monitoring and operator supervisory control.
  • the cryoprobe temperature is monitored via a temperature sensor 409 located inside the cryoprobe tip, which is connected by a wire 410 to the control system 404 .
  • Thermal sensors include thermocouples and thermistor types.
  • Body heat will unfreeze the frozen fat ball (passive thawing) in about 6-12 minutes.
  • helium is connected to the cryoprobe and operated to warm the cryoprobe for faster thawing (about 2-4 minutes). Helium properties are different than Argon, as it will heat, not cool, when expanded to atmospheric pressure.
  • An alternate method of warming is to use radio frequency (RF). In this case the cryoprobe temperature measurement is used, and the radio frequency is adjusted to create the desired cryoprobe warming temperature. RF can also be used to increase the heat to a level that will stop any bleeding. Generally, heating tissue to a temperature of least 42° C. to 45° C. causes the irreversible cellular damage needed for thermal ablation.
  • An efficient method is to divide the abdomen into quadrants as shown in FIG. 5 .
  • the I and IV quadrants, and the II and III quadrants could be treated on different days, allowing for recovery between each surgical procedure.
  • the quadrants could be treated one at a time. It is preferable to treat two non-adjacent areas, i.e. (I & IV) or (II & III), at a time.
  • the patient is preferably scanned (CT) to identify quadrant and organ dimensions, as well as how much visceral fat is removable.
  • the cryoprobe is either straight or curved.
  • a curved cryoprobe is straight when inside the body, but some cryoprobes have a 90 degree bend outside of the body entry.
  • the vacuum sleeve incorporates holes in the very end of the cryoprobe.
  • the vacuum sleeve is preferably made from a surgical metal such as stainless steel. Alternately it could be made from a surgical plastic.
  • the diameter of the cryoprobes is preferably 4 to 5 mm.
  • the surgical procedure comprises:
  • Imaging is preferably done with an ultrasound transducer operating at 12 megahertz.
  • the ultrasound transducer optionally incorporates an imaging sensor to receive the image signals.
  • an imaging sensor to receive the image signals.
  • a surgeon will be able to see about 4-10 cm depth around the ultrasound cryoprobe.
  • the preferred method for imaging is ultrasound because it is more mobile and radiation free.
  • X-Ray imaging (CT Scan) is not preferred as it emits radiation, and is a large, immobile machine.
  • Cryosurgery does not require any special patient preparation. It is important that the patient does not eat prior to surgery for four hours due to being sedated.
  • the cryoprobe As a quality check, and before use, the cryoprobe is checked by inserting it into sterile water and a cold temperature created by utilizing the cryogen gas for cooling. If a normal ice ball occurs in the water without leaking Argon, it is ready to be used.
  • Argon is the preferred cryogen, but Nitrogen (gas or liquid) may also be used.
  • lidocaine is used to numb the insertion area.
  • the irrigating solution includes lidocaine for numbing and epinephrine for blood clotting.
  • the irrigating solution is a mixture of:
  • the amount of the irrigating mixture used for irritation is as needed.
  • Fat tissues of specific anatomical landmarks are divided into areas and shown in FIGS. 2A-2B as follows:
  • FIG. 4 a simplified schematic of the cryogen supply and control system 404 is shown.
  • a high pressure Argon gas cylinder 401 connects to a cylinder supply valve 402 .
  • a supply line 403 connects the cylinder to a system controller 404 .
  • a supply line 405 and return line 406 connect to the cryoprobe 407 .
  • An internal temperature sensor 409 connects to the control system with a connecting wire 410 .
  • Spent Argon is released through a vent 408 .
  • a surgeon computer interface 411 to the control system 404 allows the surgeon to monitor and control the cryoprobe freezing.
  • FIG. 6 is a perspective view of the vacuum sleeve, illustrating the perforated holes at the distal end of the vacuum sleeve.
  • the holes are either an evenly geometric pattern, as illustrated, or a random pattern.
  • the holes are generally conceived to be either elliptical or circular. In one embodiment of the invention, the holes are about 3 mm in diameter, with centers spaced about 10 mm apart. However, this is not strict requirement.
  • the surgical procedure begins when the cryogenic equipment is ready, and the cryoprobe has been confirmed to be functional.
  • the patient is connected to monitors that track heart rate, blood pressure, and pulse.
  • the area where the applicators or cryoprobe are to be inserted will be shaved, sterilized, and covered with a sterile drape.
  • the surgeon only needs to make a very small skin incision is made at the site. The surgeon then performs a percutaneous procedure and inserts the thin, needle-size cryoprobes.
  • cryoprobe(s) aside from the cryoprobe(s), transducer, irrigating fluid, and vacuum sleeve, nothing else enters the body.
  • RF warming is used to free up any sticking of the cryoprobe.
  • a different cryoprobe (not illustrated) is used that is capable of RF heating.
  • the computer is capable of communicating with a temperature sensor and utilizing the temperature sensor for control. Additionally, the computer receives the ultrasound transducer output signal and interprets it into a visual image.
  • the computer may be a desktop computer, a lap top computer, a server, a workstation, a handheld computer, a tablet computer, a single board computer, etc.
  • the computer is in near proximity to the cryogenic supply unit and integrated into the equipment as shown in FIG. 4 .
  • central computer or computer system are intended to refer to a computer-related entity, comprising either hardware, a combination of hardware and software, software, or software in execution capable of performing the embodiments described.
  • the disclosed embodiments which use the central computer refer to being interfaced to and controlled by a computer readable storage medium having stored thereon a computer program.
  • the computer readable storage medium may include a plurality of components such as one or more of electronic components, hardware components, and/or computer software components. These components may include one or more computer readable storage media that generally store instructions such as software, firmware and/or assembly language for performing one or more portions of one or more implementations or embodiments of an algorithm as discussed herein. These computer readable storage media are generally non-transitory and/or tangible.
  • Examples of such a computer readable storage medium include a recordable data storage medium of a computer and/or storage device.
  • the computer readable storage media may employ, for example, one or more of a magnetic, electrical, optical, biological, and/or atomic data storage medium. Further, such media may take the form of, for example, floppy disks, magnetic tapes, CD-ROMs, DVD-ROMs, hard disk drives, and/or solid-state or electronic memory. Other forms of non-transitory and/or tangible computer readable storage media not list may be employed with the disclosed embodiments.
  • Such components can be combined or divided in an implementation of a computer system. Further, such components may include a set and/or series of computer instructions written in or implemented with any of a number of programming languages, as will be appreciated by those skilled in the art. Computer instructions are executed by at least one central processing unit. In addition, other forms of computer readable media such as a carrier wave may be employed to embody a computer data signal representing a sequence of instructions that when executed by one or more computers causes the one or more computers to perform one or more portions of one or more implementations or embodiments of a sequence.

Abstract

The embodied invention is a method of removing intraperitoneal fat by using a freezing cryoprobe and inserting it into the abdominal cavity. The freezing cryoprobe is covered by a vacuum sleeve which provides for a method for abdominal fat removal once the cells are damaged. A multi-step surgical procedure is used to freeze, irrigate, and remove the destroyed fat tissue. Also, an ultrasonic transmitter is inserted into an outer cryoprobe sheath to assess organ position with the advantage of an internal transmitter which greatly aids in organ identification.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional application of U.S. application Ser. No. 16/266,037 filed on Feb. 2, 2019. The prior filed application is hereby incorporated by reference.
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
  • Not applicable.
  • REFERENCE TO SEQUENCE LISTING, A TABLE, OR COMPUTER PROGRAM LISTING
  • Not applicable.
  • BACKGROUND OF THE INVENTION (1) Field of the Invention
  • This invention is directed to
  • (2) Description of Related Art
  • A study from the National Center for Health Statistics at the CDC showed that 39.6% of US adults age 20 and older were obese as of 2015-2016 (37.9% for men and 41.1% for women). Additionally, studies correlate heart attacks not just to being overweight, but to the amount of intraperitoneal fat (also called visceral fat).
  • Obesity in the United States is a major health issue, resulting in numerous diseases, specifically increased risk of certain types of cancer, coronary artery disease, type 2 diabetes, stroke, as well as significant economic costs.
  • If a surgical procedure to remove intraperitoneal fat could be developed there would be fewer heart attacks and improved health.
  • Currently, there is no surgical method available to remove intraperitoneal fat. The use of liposuction is not desirable as the process includes mechanical liquification of fat, which would damage internal organs.
  • Intraperitoneal fat is known to be difficult to remove by diet and exercise.
  • Cryosurgery is one method of killing tissue and is used for cancer treatments. It is a candidate for removal of intraperitoneal fat under the right conditions. However, current methods and equipment is inadequate to avoid internal organ damage when organs are interspersed in the intraperitoneal fat. Internal organs are likely to be damaged from freezing fat tissue if there is no methodology to identify organ positions to ensure that no damage is created. Additionally, current cryosurgery methods do not address removal of frozen tissue during surgery.
  • Others have worked in the field of cryogen treatments such as U.S. Pat. No. 6,041,787 where the system is described and its benefits. U.S. Pat. No. 5,531,742 describes computerized methods to monitor the frozen region and provide feedback to the surgeon.
  • U.S. Pat. No. 5,112,302 describes liposuction, which is used for removal of subcutaneous fat. The removal of fat is based on mechanical liquification of fat and then the fat is removed by vacuum. This motion of the cannula in the fat is very traumatic, and complications such as seromas, numbness, skin infections, or an internal puncture from the moving cannula can occur.
  • Cryosurgery is used in cancer treatment by utilizing liquid nitrogen or argon gas on cancerous tissue to destroy it. The gas is used to cool a cryoprobe which in turn is used to freeze an internal tumor and surrounding tissue. For an external tumor, liquid nitrogen is sprayed directly to the cancer cells or swabbed onto the tumor with a cotton swab.
  • There is need in the art for a way to surgically remove intraperitoneal and subcutaneous fat without damage to internal organs for improved health.
  • BRIEF SUMMARY OF THE INVENTION
  • The embodied invention is a method of removing intraperitoneal fat by using a cryoprobe and inserting it into the abdominal cavity. The cryoprobe is covered by a vacuum sleeve which provides for a method for intraperitoneal fat removal once the cells are damaged. A multi-step surgical procedure is used to freeze, irrigate, and remove the destroyed fat tissue. Also, an ultrasonic transmitter is inserted into an outer cryoprobe sheath to assess organ position with the advantage of an internal transmitter which greatly aids in organ identification.
  • BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)
  • FIG. 1 shows a cross section of a cryogenic cryoprobe tip.
  • FIGS. 2A-2D show fat tissue in a horizontal cross section of a human abdomen, and placement of a cryoprobe.
  • FIG. 3A-3F show the end of cryoprobe and how it is used in surgery.
  • FIG. 3G-3K show the end of the cryoprobe and how it is used to create an ice ball of fat tissue, irrigate it, and remove it.
  • FIG. 4 shows how a cryogenic gas is connected to the cryoprobe.
  • FIG. 5 shows how the abdomen is dived for repetitive treatments.
  • FIG. 6 is a perspective view of the vacuum sleeve, illustrating the end holes.
  • DETAILED DESCRIPTION OF THE INVENTION
  • When cryogenically treating cancer tumors inside the body, liquid nitrogen or argon flows through a hollow instrument called a cryoprobe, which is placed inside (or in contact with) the tumor to freeze it. Similarly, a cryoprobe can be used to freeze fat tissue.
  • In the embodied invention, a surgeon uses internal imaging equipment (ultrasound or MRI) to guide the cryoprobe to the correct location and monitor the freezing of the fat cells to avoid damage to nearby organs. When the cryogen (argon or nitrogen) cooled cryoprobe contacts the fat tissue, a ball of frozen tissue forms around the cryoprobe, killing the cells. The cryoprobe is put into the fat tissue through the skin (percutaneously). The frozen tissue is then thawed and removed. Sometimes, more than one freeze-thaw cycle is be used.
  • FIG. 1 (not to scale) is a cross section of the cryoprobe. The cryoprobe is typically 3-6 mm in diameter and the length 102 of the tip 103 is about 1.5 mm or so. The exposed tube length 101 is about 3-6 cm long. These dimensions are not strict requirements. The distal exposed section 101 of the cryoprobe is a cryocooler to reach the temperature needed to kill peritoneal fat cells. It is delineated by the insulation 107 along the length of the cryoprobe outer shaft. The insulation is preferably an insulating plastic.
  • The uninsulated length 101 is a cryocooler and freezes fat tissue from the cryoprobe surface outward. When the desired amount of tissue has been frozen, cryogen flow is stopped, and the tissue is allowed to thaw internally. When high pressure argon gas is used as the cryogen to cool the tip of the cryoprobe, it flows through a small diameter inner tube 105, and expands at the end of the inner tube 106. The expanding Argon gas cools the cryoprobe to a very low temperature due to the Joule-Thompson effect. The low pressure Argon gas is then routed through an exhaust chamber 104 to be vented away from the patient. No Argon gas is released inside the patient's body. U.S. Pat. Nos. 7,479,139 and 7,846,154 are examples of cryoprobes.
  • The term “high-pressure gas” refers to gas pressures that will cause a Joule-Thomson cooling of cryoprobes to −40° C. and lower. In the case of argon gas, for example, “high-pressure” argon is typically between 3000 psi and 4500 psi, though somewhat higher and lower pressures may be used. For a warming gas such as Helium, the working high pressure range is typically 1800-2500 psi.
  • Since freezing originates from the small uninsulated tip of the cryoprobe, cryosurgery can be confined to a small region of tissue, sparing the surrounding healthy tissue. The freezing process is precise and controlled, as the freezing interface in the fat tissue is sharp and propagates slowly from the tip. A small cryoprobe having a diameter of around 4 mm can produce a 3.5 cm diameter frozen ellipsoid ball to treat a relatively large tissue region in a few minutes. In general, cryosurgery does not create a lot of complications and has low patient morbidity. Cryosurgery produces excellent therapeutic results with less distress at a lower cost. In addition, retreatment is possible.
  • FIG. 2A is a cross sectional image of abdominal fat tissue compartments. Fat tissues of specific areas are shown in cross hatching:
    • 201 subcutaneous fat,
    • 202 deep subcutaneous fat, and
    • 203 mesenteric visceral (intraperitoneal) fat.
  • FIG. 2B shows a cryoprobe 204 inserted into the abdomen and creating an ice ball 205 of frozen intraperitoneal fat 203.
  • FIG. 2C shows a cryoprobe 204 inserted into the abdomen and creating an ice ball 206 of frozen retro-intraperitoneal fat 207. FIG. 2D shows a cryoprobe and an ice ball 208 of frozen subcutaneous fat.
  • In the surgical procedure, the Argon gas typically creates a cryoprobe end temperature of −40° C. for freezing fat tissue. However, only a temperature of −10° C. (or lower) is needed for cell destruction, and the cryoprobe end is alternately designed for less than −10° C. As shown in FIG. 4, Argon gas (or other cryogen gas) is supplied by a high pressure cylinder 401. A shutoff valve 402 on top of the cylinder is connected to a supply line 403 which is connected to a cryoprobe control system 404. The control system provides temperature regulation by regulating the amount of Argon allowed to a cryoprobe supply line 405. The return gas from the cryoprobe is routed through a return line 406 and is ultimately vented 408 from the cryoprobe control system. The control system includes needed piping and valve and automated computer control. A computer interface 411 provides for monitoring and operator supervisory control.
  • The cryoprobe temperature is monitored via a temperature sensor 409 located inside the cryoprobe tip, which is connected by a wire 410 to the control system 404. Thermal sensors include thermocouples and thermistor types.
  • Body heat will unfreeze the frozen fat ball (passive thawing) in about 6-12 minutes. In an alternate embodiment, helium is connected to the cryoprobe and operated to warm the cryoprobe for faster thawing (about 2-4 minutes). Helium properties are different than Argon, as it will heat, not cool, when expanded to atmospheric pressure. An alternate method of warming is to use radio frequency (RF). In this case the cryoprobe temperature measurement is used, and the radio frequency is adjusted to create the desired cryoprobe warming temperature. RF can also be used to increase the heat to a level that will stop any bleeding. Generally, heating tissue to a temperature of least 42° C. to 45° C. causes the irreversible cellular damage needed for thermal ablation.
  • Multiple freezing sites can be done in a single surgical session. An efficient method is to divide the abdomen into quadrants as shown in FIG. 5. For example, the I and IV quadrants, and the II and III quadrants could be treated on different days, allowing for recovery between each surgical procedure. Alternately, the quadrants could be treated one at a time. It is preferable to treat two non-adjacent areas, i.e. (I & IV) or (II & III), at a time. To that end, the patient is preferably scanned (CT) to identify quadrant and organ dimensions, as well as how much visceral fat is removable.
  • The cryoprobe is either straight or curved. A curved cryoprobe is straight when inside the body, but some cryoprobes have a 90 degree bend outside of the body entry. The vacuum sleeve incorporates holes in the very end of the cryoprobe. The vacuum sleeve is preferably made from a surgical metal such as stainless steel. Alternately it could be made from a surgical plastic. The diameter of the cryoprobes is preferably 4 to 5 mm.
  • The surgical procedure comprises:
    • 1. Create a small percutaneous incision for the cryoprobe to pass through.
    • 2. FIG. 3A. Insert the cryoprobe and vacuum sleeve 303 as guided by an external ultrasound camera. Locate the cryoprobe tip 304 in a desired fatty tissue volume that will be removed. The cryoprobe includes outer an outer tubing 301, an outer insulation covering 302, an inner high pressure tubing 305, a penetration tip 304, and a temperature sensor/wire (not shown).
    • 3. FIG. 3B. Remove the cryoprobe and leave the vacuum sleeve in place.
    • 4. FIG. 3C. Insert an ultrasound transducer 306 into the vacuum sleeve and position at the end. Examine volume and position of fatty tissue. Determine how much cooling may be applied to the fatty tissue volume. Verify organ position with ultrasonic transducer/camera so that no organ tissue will be damaged. If needed, back out the vacuum sleeve and ultrasound transducer to avoid internal organs.
    • 5. FIG. 3D. Withdraw the ultrasound transducer from the vacuum sleeve. The vacuum sleeve stays in the body.
    • 6. FIG. 3E. Re-insert the cryoprobe into the vacuum sleeve to the previous cryoprobe position.
    • 7. FIG. 3F. Withdraw the external sleeve 303 about 2-3 cm to reveal the cryoprobe tip so that an ice ball of frozen fat tissue can be made. The distal end 316 of the cryoprobe is the cryocooler.
    • 8. Turn on the cryogenic control system and adjust the freezing cryoprobe temperature (about −40 to −50° C. to create the desired volume of frozen fat tissue (i.e. ice ball) 307. Monitor the freezing volume by using an external ultrasound camera. Turn off the cryogen flow when ice ball 307 freezing is completed.
    • 9. FIG. 3H. Move the vacuum sleeve into the body to the previous position in step 5.
    • 10. FIG. 3I. Completely withdraw the cryoprobe and leave the vacuum sleeve in place. The cryoprobe should easily separate from the ice ball.
    • 11. FIG. 3J. Connect a cylinder/syringe 308 to a Leur Lock 130 using a connecting tubing 311. Push saline solution 312 into the vacuum sleeve 303 into the ice ball 307. Connect irrigation water (saline solution) 312 through the Leur Lock and vacuum sleeve into the ice ball 307. The end of the vacuum sleeve 303 has holes 315 that facilitate even irrigation coverage. Inject the desired amount of irrigation fluid into the freezing area to liquify the frozen fat tissue. Disconnect the irrigation fluid from the external sleeve.
    • 12. FIG. 3K. Connect an evacuating syringe 313 to the Leur Lock 130 and apply a vacuum to remove the liquified frozen volume 134 a,b. Monitor the removal area using an external ultrasound camera. Oscillate the external sleeve in and out of the abdomen slightly to aid in removal of liquified fat tissue.
    • 13. When all of the desired liquified fat tissue has been removed, withdraw the vacuum sleeve.
    • 14. Inspect and close the skin opening. The opening in the skin is covered with a bandage. Sutures are applied if needed.
  • Imaging is preferably done with an ultrasound transducer operating at 12 megahertz. The ultrasound transducer optionally incorporates an imaging sensor to receive the image signals. Typically, a surgeon will be able to see about 4-10 cm depth around the ultrasound cryoprobe. The preferred method for imaging is ultrasound because it is more mobile and radiation free. X-Ray imaging (CT Scan) is not preferred as it emits radiation, and is a large, immobile machine.
  • Cryosurgery does not require any special patient preparation. It is important that the patient does not eat prior to surgery for four hours due to being sedated.
  • As a quality check, and before use, the cryoprobe is checked by inserting it into sterile water and a cold temperature created by utilizing the cryogen gas for cooling. If a normal ice ball occurs in the water without leaking Argon, it is ready to be used.
  • Argon is the preferred cryogen, but Nitrogen (gas or liquid) may also be used.
  • There is no particular limitation to amount of procedures that can be performed to remove fatty tissue.
  • To aid in pain control, lidocaine is used to numb the insertion area.
  • In an additional embodiment, the irrigating solution includes lidocaine for numbing and epinephrine for blood clotting. In an exemplary embodiment, the irrigating solution is a mixture of:
    • 1. 400 ml saline solution (sterile water and 0.9% by weight NaCl),
    • 2. 10 ml sodium bicarbonate-buffer (about 8.4% by weight), and
    • 3. 50 ml of water with
      • a. 0.05% lidocaine by volume, and
      • b. epinephrine at 1:1,000,000 by volume.
  • The amount of the irrigating mixture used for irritation is as needed.
  • Fat tissues of specific anatomical landmarks are divided into areas and shown in FIGS. 2A-2B as follows:
    • 1. subcutaneous fat 201,
    • 2. deep subcutaneous fat 202, and
    • 3. intraperitoneal visceral fat 203, and
    • 4. other non-shaded tissue and vertebrae.
  • In FIG. 4, a simplified schematic of the cryogen supply and control system 404 is shown. A high pressure Argon gas cylinder 401 connects to a cylinder supply valve 402. A supply line 403 connects the cylinder to a system controller 404. A supply line 405 and return line 406 connect to the cryoprobe 407. An internal temperature sensor 409 connects to the control system with a connecting wire 410. Spent Argon is released through a vent 408. A surgeon computer interface 411 to the control system 404 allows the surgeon to monitor and control the cryoprobe freezing.
  • FIG. 6 is a perspective view of the vacuum sleeve, illustrating the perforated holes at the distal end of the vacuum sleeve. The holes are either an evenly geometric pattern, as illustrated, or a random pattern. The holes are generally conceived to be either elliptical or circular. In one embodiment of the invention, the holes are about 3 mm in diameter, with centers spaced about 10 mm apart. However, this is not strict requirement.
  • It is important that a specially trained physician performs the surgical procedure. Preferably it is done on an outpatient basis. The surgical procedure begins when the cryogenic equipment is ready, and the cryoprobe has been confirmed to be functional.
  • During the procedure, the patient is connected to monitors that track heart rate, blood pressure, and pulse. The area where the applicators or cryoprobe are to be inserted will be shaved, sterilized, and covered with a sterile drape.
  • The surgeon only needs to make a very small skin incision is made at the site. The surgeon then performs a percutaneous procedure and inserts the thin, needle-size cryoprobes.
  • In a preferred embodiment, aside from the cryoprobe(s), transducer, irrigating fluid, and vacuum sleeve, nothing else enters the body.
  • The entire procedure will only take one to three hours.
  • In an alternate embodiment, RF warming is used to free up any sticking of the cryoprobe. A different cryoprobe (not illustrated) is used that is capable of RF heating.
  • The computer is capable of communicating with a temperature sensor and utilizing the temperature sensor for control. Additionally, the computer receives the ultrasound transducer output signal and interprets it into a visual image. The computer may be a desktop computer, a lap top computer, a server, a workstation, a handheld computer, a tablet computer, a single board computer, etc. Preferably the computer is in near proximity to the cryogenic supply unit and integrated into the equipment as shown in FIG. 4.
  • As used herein the terms central computer or computer system are intended to refer to a computer-related entity, comprising either hardware, a combination of hardware and software, software, or software in execution capable of performing the embodiments described. The disclosed embodiments which use the central computer refer to being interfaced to and controlled by a computer readable storage medium having stored thereon a computer program. The computer readable storage medium may include a plurality of components such as one or more of electronic components, hardware components, and/or computer software components. These components may include one or more computer readable storage media that generally store instructions such as software, firmware and/or assembly language for performing one or more portions of one or more implementations or embodiments of an algorithm as discussed herein. These computer readable storage media are generally non-transitory and/or tangible. Examples of such a computer readable storage medium include a recordable data storage medium of a computer and/or storage device. The computer readable storage media may employ, for example, one or more of a magnetic, electrical, optical, biological, and/or atomic data storage medium. Further, such media may take the form of, for example, floppy disks, magnetic tapes, CD-ROMs, DVD-ROMs, hard disk drives, and/or solid-state or electronic memory. Other forms of non-transitory and/or tangible computer readable storage media not list may be employed with the disclosed embodiments.
  • A number of such components can be combined or divided in an implementation of a computer system. Further, such components may include a set and/or series of computer instructions written in or implemented with any of a number of programming languages, as will be appreciated by those skilled in the art. Computer instructions are executed by at least one central processing unit. In addition, other forms of computer readable media such as a carrier wave may be employed to embody a computer data signal representing a sequence of instructions that when executed by one or more computers causes the one or more computers to perform one or more portions of one or more implementations or embodiments of a sequence.
  • While various embodiments of the present invention have been described, the invention may be modified and adapted to various operational methods to those skilled in the art. Therefore, this invention is not limited to the description and figure shown herein, and includes all such embodiments, changes, and modifications that are encompassed by the scope of the claims.

Claims (3)

I claim:
1. Apparatus for removing intraperitoneal fat and identifying a correct position of a cryoprobe comprising:
A) a cryoprobe further comprising:
a) an insulated cryoprobe tube with a closed distal operating tip,
b) said distal operating tip is non-insulated,
c) said distal operating tip comprises a cryocooler operable to cool to cryoablation temperatures of intraperitoneal fat surrounding said distal operating tip,
d) said cryoprobe tube incorporates a coaxial cryogen exhaust chamber for exhausting cold cryogen from said cryocooler, and
e) a coaxial cryogen gas delivery tube inside said cryoprobe tube,
B) an outer vacuum sleeve incorporating a plurality of perforations at a distal end,
C) said outer vacuum sleeve is coaxial to said cryoprobe and operable to move relative to said cryoprobe,
D) internal imaging equipment,
E) whereby the functions of
a) identifying a correct cryoprobe position utilizing said internal imaging equipment, and
b) identifying positions of internal organs utilizing said internal imaging equipment, is added,
F) whereby said cryoprobe is operable to freeze intraperitoneal fat, and
G) whereby said outer vacuum sleeve is operable to remove liquified intraperitoneal fat.
2. The apparatus according to claim 1, wherein:
A) said plurality of perforations are arranged in a geometric pattern or a random pattern, and
B) said perforations are substantially 3 mm in diameter with centers spaced substantially 10 mm apart.
3. The apparatus according to claim 1, wherein said internal imaging equipment comprises an ultrasound sensor and a display.
US16/840,363 2019-02-02 2020-04-04 Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat Active 2041-04-12 US11844559B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/840,363 US11844559B2 (en) 2019-02-02 2020-04-04 Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/266,037 US10610280B1 (en) 2019-02-02 2019-02-02 Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
US16/840,363 US11844559B2 (en) 2019-02-02 2020-04-04 Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/266,037 Division US10610280B1 (en) 2019-02-02 2019-02-02 Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat

Publications (2)

Publication Number Publication Date
US20200246054A1 true US20200246054A1 (en) 2020-08-06
US11844559B2 US11844559B2 (en) 2023-12-19

Family

ID=70056384

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/266,037 Active US10610280B1 (en) 2019-02-02 2019-02-02 Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
US16/840,363 Active 2041-04-12 US11844559B2 (en) 2019-02-02 2020-04-04 Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/266,037 Active US10610280B1 (en) 2019-02-02 2019-02-02 Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat

Country Status (1)

Country Link
US (2) US10610280B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022251813A1 (en) * 2021-05-24 2022-12-01 B2M Medical, Inc. Method and system of removing visceral fat

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610280B1 (en) * 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
US11717638B2 (en) 2021-02-09 2023-08-08 Thuy Doan Method for anesthetizing the lips

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946460A (en) * 1989-04-26 1990-08-07 Cryo Instruments, Inc. Apparatus for cryosurgery
US6032675A (en) * 1997-03-17 2000-03-07 Rubinsky; Boris Freezing method for controlled removal of fatty tissue by liposuction
US7479139B2 (en) * 2002-01-04 2009-01-20 Galil Medical Ltd. Apparatus and method for protecting tissues during cryoablation
US20090118722A1 (en) * 2006-10-31 2009-05-07 Ebbers Edward A Method and apparatus for cooling subcutaneous lipid-rich cells or tissue
US10610280B1 (en) * 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378018D1 (en) 1982-05-17 1988-10-27 Andrzej Kamil Drukier Cryosurgical apparatus, especially for the cryosurgery of deeply lying lesions
FR2619281B2 (en) 1987-07-08 1990-01-05 Lafon Labor GALENIC FORM COMPRISING MICROPARTICLES AND PROCESS FOR PREPARING THE SAME
US5112302A (en) 1990-07-16 1992-05-12 Cucin Robert L Method and apparatus for performing liposuction
ZA917281B (en) 1990-09-26 1992-08-26 Cryomedical Sciences Inc Cryosurgical instrument and system and method of cryosurgery
US5531742A (en) 1992-01-15 1996-07-02 Barken; Israel Apparatus and method for computer controlled cryosurgery
US6161543A (en) 1993-02-22 2000-12-19 Epicor, Inc. Methods of epicardial ablation for creating a lesion around the pulmonary veins
US5433717A (en) 1993-03-23 1995-07-18 The Regents Of The University Of California Magnetic resonance imaging assisted cryosurgery
US5891617A (en) 1993-09-15 1999-04-06 Organogenesis Inc. Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing
US5672172A (en) 1994-06-23 1997-09-30 Vros Corporation Surgical instrument with ultrasound pulse generator
US6039730A (en) 1996-06-24 2000-03-21 Allegheny-Singer Research Institute Method and apparatus for cryosurgery
US5899897A (en) 1996-09-26 1999-05-04 Allegheny-Singer Research Institute Method and apparatus for heating during cryosurgery
DE69738378T2 (en) 1996-10-22 2008-11-27 St. Jude Medical, Atrial Fibrillation Division, Inc., Minnetonka DEVICE FOR TREATING MEDICAL-REFRACTORY FORWARD FIBRILLATIONS
CA2271651C (en) 1996-11-29 2003-11-25 Life Imaging Systems Inc. System, employing three-dimensional ultrasonographic imaging, for assisting in guiding and placing medical instruments
US6270494B1 (en) 1996-12-26 2001-08-07 Cryogen, Inc. Stretchable cryoprobe sheath
AU6865298A (en) 1997-03-17 1998-10-12 Boris Rubinsky The use of cryoprotective agent compounds during cryosurgery
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
ES2319660T3 (en) 1998-05-01 2009-05-11 University Of Pittsburgh USE OF MIOBLASTS IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT URINARY INCONTINENCE OF EFFORT.
US6139544A (en) 1999-05-26 2000-10-31 Endocare, Inc. Computer guided cryosurgery
US20020077550A1 (en) 1999-10-05 2002-06-20 Rabiner Robert A. Apparatus and method for treating gynecological diseases using an ultrasonic medical device operating in a transverse mode
US6494844B1 (en) 2000-06-21 2002-12-17 Sanarus Medical, Inc. Device for biopsy and treatment of breast tumors
WO2002032318A1 (en) 2000-10-16 2002-04-25 Sanarus Medical, Inc. Device for biopsy of tumors
WO2007086056A2 (en) 2006-01-26 2007-08-02 Galil Medical Ltd. Device for coordinated insertion of a plurality of cryoprobes
US20020188287A1 (en) 2001-05-21 2002-12-12 Roni Zvuloni Apparatus and method for cryosurgery within a body cavity
CN2458995Y (en) 2001-01-20 2001-11-14 中国科学院理化技术研究所 Submersion cooling type cryoprobe capable of speedup of quick heating and thawing frozen tumor tissue
US9345460B2 (en) 2001-04-24 2016-05-24 Cardiovascular Technologies, Inc. Tissue closure devices, device and systems for delivery, kits and methods therefor
JP2005503227A (en) 2001-09-27 2005-02-03 ガリル メディカル リミテッド Apparatus and method for cryosurgical treatment of breast tumors
US8840608B2 (en) 2002-03-15 2014-09-23 The General Hospital Corporation Methods and devices for selective disruption of fatty tissue by controlled cooling
CA2441489A1 (en) 2003-09-12 2005-03-12 Jocelyn Tortal Inducing and contouring ice formation
JP2006034841A (en) 2004-07-30 2006-02-09 Hitachi Medical Corp Thermotherapy apparatus and diagnostic imaging apparatus
US7846154B2 (en) 2004-12-06 2010-12-07 Galil Medical Ltd. Gas-heated gas-cooled cryoprobe utilizing electrical heating and a single gas source
US7713266B2 (en) 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US20070016274A1 (en) 2005-06-29 2007-01-18 Boveja Birinder R Gastrointestinal (GI) ablation for GI tumors or to provide therapy for obesity, motility disorders, G.E.R.D., or to induce weight loss
US20050240239A1 (en) 2005-06-29 2005-10-27 Boveja Birinder R Method and system for gastric ablation and gastric pacing to provide therapy for obesity, motility disorders, or to induce weight loss
US20070031338A1 (en) 2005-08-02 2007-02-08 Zabinski Peter P Embolized cryoablation for treatment of tumors
GB0604602D0 (en) 2006-03-07 2006-04-19 Univ Edinburgh Ruthenium (II) compounds
GB0610062D0 (en) 2006-05-19 2006-06-28 Univ Edinburgh Ruthenium (ll) compounds
CN101028525B (en) 2006-09-01 2010-12-08 上海美恩生物技术有限公司 Use of tumor caryon single-antibody in physical therapeutic tumor as synergist
US8663083B2 (en) 2006-12-08 2014-03-04 Koninklijke Philips N.V. System, method, computer-readable medium, and use for planning combined therapy
US8409185B2 (en) 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US8690864B2 (en) 2007-03-09 2014-04-08 Covidien Lp System and method for controlling tissue treatment
WO2008131302A2 (en) 2007-04-19 2008-10-30 The Foundry, Inc. Methods and apparatus for reducing sweat production
WO2008156353A1 (en) 2007-06-18 2008-12-24 Wittens Cornelis Hendrikus Ann Cryo probe, method for shaping a cryo probe
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
US20090018627A1 (en) 2007-07-13 2009-01-15 Juniper Medical, Inc. Secure systems for removing heat from lipid-rich regions
US20090018624A1 (en) 2007-07-13 2009-01-15 Juniper Medical, Inc. Limiting use of disposable system patient protection devices
US20090018626A1 (en) 2007-07-13 2009-01-15 Juniper Medical, Inc. User interfaces for a system that removes heat from lipid-rich regions
US20090018625A1 (en) 2007-07-13 2009-01-15 Juniper Medical, Inc. Managing system temperature to remove heat from lipid-rich regions
JP5474791B2 (en) 2007-08-21 2014-04-16 ゼルティック エステティックス インコーポレイテッド Monitoring of cooling of subcutaneous lipid-rich cells such as cooling of adipose tissue
ES2637165T3 (en) 2007-11-21 2017-10-11 Adagio Medical, Inc. Flexible multitubular cryoprobe
US20090192505A1 (en) 2007-12-05 2009-07-30 Reset Medical, Inc. Method for cryospray ablation
US20090156958A1 (en) 2007-12-12 2009-06-18 Mehta Bankim H Devices and methods for percutaneous energy delivery
US20090198093A1 (en) 2008-02-06 2009-08-06 Oliver Meissner System and method for combined embolization and ablation therapy
JP5062035B2 (en) 2008-05-23 2012-10-31 住友化学株式会社 Polypropylene resin composition and film
US8275442B2 (en) 2008-09-25 2012-09-25 Zeltiq Aesthetics, Inc. Treatment planning systems and methods for body contouring applications
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
EP2373239B1 (en) 2008-12-22 2013-08-14 Myoscience, Inc. Integrated cryosurgical system with refrigerant and electrical power source
DE112010001833T5 (en) 2009-04-30 2012-08-30 Alma Lasers Ltd. Establishment and method of dermatological treatment
CN102625676A (en) 2009-07-28 2012-08-01 纽韦弗医疗设备公司 Energy delivery systems and uses thereof
US20110184402A1 (en) 2009-11-02 2011-07-28 Cpsi Biotech Flexible Cryogenic Probe Tip
IN2012DN03815A (en) 2009-11-03 2015-08-28 Dsm Ip Assets Bv
IN2012DN05147A (en) 2009-11-09 2015-10-23 Cardiovascular Technologies Inc
US20110263921A1 (en) 2009-12-31 2011-10-27 Anthony Vrba Patterned Denervation Therapy for Innervated Renal Vasculature
US20120089211A1 (en) 2010-04-08 2012-04-12 Myoscience, Inc. Methods and apparatus for cryogenically treating multiple tissue sites with a single puncture
AU2011239637B2 (en) 2010-04-13 2014-12-11 Atricure, Inc. Methods and devices for pericardial access
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US9039688B2 (en) 2010-12-13 2015-05-26 Myoscience, Inc. Method for reducing hyperdynamic facial wrinkles
US20130261368A1 (en) 2011-09-23 2013-10-03 Alan N. Schwartz Non-invasive and minimally invasive and tightly targeted minimally invasive therapy methods and devices for parathyroid treatment
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
CN103732688B (en) 2011-06-03 2016-12-21 沙特基础全球技术有限公司 Polyetherimide/Poly-s 179 the goods of sterilization
KR101942539B1 (en) 2011-06-03 2019-01-25 사빅 글로벌 테크놀러지스 비.브이. Sterilized polyetherimide articles
WO2013013099A1 (en) 2011-07-19 2013-01-24 Adagio Medical, Inc. Methods and devices for the treatment of atrial fibrillation
WO2013044182A1 (en) 2011-09-22 2013-03-28 The George Washington University Systems and methods for visualizing ablated tissue
WO2013106859A1 (en) 2012-01-13 2013-07-18 Myoscience, Inc. Cryogenic needle with freeze zone regulation
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US9566105B2 (en) 2012-02-07 2017-02-14 Cpsi Holdings Llc Dual thermal ablation device and method of use
WO2013149034A2 (en) 2012-03-28 2013-10-03 Cibiem, Inc. Carotid body modulation planning and assessment
CN104321325B (en) 2012-05-24 2016-11-16 诺华股份有限公司 Pyrrolopyrrole alkanone compound
WO2014043803A1 (en) 2012-09-20 2014-03-27 Genomedx Biosciences, Inc. Thyroid cancer diagnostics
ES2665773T3 (en) 2012-10-22 2018-04-27 Dsm Ip Assets B.V. Smooth hydrolysis of rice bran proteins
US9545523B2 (en) 2013-03-14 2017-01-17 Zeltiq Aesthetics, Inc. Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue
US9668800B2 (en) 2013-03-15 2017-06-06 Myoscience, Inc. Methods and systems for treatment of spasticity
US20140350536A1 (en) 2013-03-15 2014-11-27 Myoscience, Inc. Cryogenic Blunt Dissection Methods and Devices
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
WO2014160698A1 (en) 2013-03-26 2014-10-02 Celgene Corporation SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015021434A2 (en) 2013-08-09 2015-02-12 Cytrellis Biosystems, Inc. Methods and apparatuses for skin treatment using non-thermal tissue ablation
TWI646092B (en) 2013-08-26 2019-01-01 拜耳作物科學股份有限公司 Compound with insecticidal activity
JP6266941B2 (en) 2013-10-07 2018-01-24 小林 正則 Eyelid drooping prevention tape
AU2014346919B2 (en) 2013-11-05 2017-02-02 Novartis Ag Compositions and methods for modulating Farnesoid X receptors
US10154873B2 (en) 2013-11-14 2018-12-18 Rm2 Technology Llc Methods, systems, and apparatuses for delivery of electrolysis products
US20150141866A1 (en) 2013-11-18 2015-05-21 Martin L. Mayse System and method for evaluation of the pleural space
EP3080631A1 (en) 2013-12-10 2016-10-19 Koninklijke Philips N.V. Magnetic resonance coil assembly for fiducial markers
PL3083564T3 (en) 2013-12-20 2018-12-31 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
US20170165105A1 (en) 2014-01-31 2017-06-15 The General Hospital Corporation Methods, kits, and cooling devices for disrupting function of one or more sebaceous glands
EP3099259A1 (en) 2014-01-31 2016-12-07 Zeltiq Aesthetics, Inc. Treatment systems and methods for affecting glands and other targeted structures
US20150232785A1 (en) 2014-02-14 2015-08-20 E I Du Pont De Nemours And Company Polysaccharides for viscosity modification
US20150305623A1 (en) 2014-04-23 2015-10-29 Invuity, Inc. Methods for localizing and treating a parathyroid adenoma
CA2949289A1 (en) 2014-05-29 2015-12-03 E. I. Du Pont De Nemours And Company Enzymatic synthesis of soluble glucan fiber
US10568759B2 (en) 2014-08-19 2020-02-25 Zeltiq Aesthetics, Inc. Treatment systems, small volume applicators, and methods for treating submental tissue
US10935174B2 (en) 2014-08-19 2021-03-02 Zeltiq Aesthetics, Inc. Stress relief couplings for cryotherapy apparatuses
WO2016079331A1 (en) 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for enhancing the effect of radiotherapy
WO2016079330A1 (en) 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for local drug release
WO2016079332A1 (en) 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for improving immunotherapy
WO2016094420A1 (en) 2014-12-08 2016-06-16 The Regents Of The University Of Michigan Non-coding rnas and uses thereof
JP2016116795A (en) 2014-12-22 2016-06-30 株式会社ニトムズ Pressure-sensitive adhesive cleaner for antibacterial treatment
JP6770519B2 (en) 2014-12-23 2020-10-14 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company Cellulose produced by enzymes
EP3045132A1 (en) 2015-01-13 2016-07-20 Starpharm Cosmetic treatment of brown skin stains
US10568687B2 (en) 2015-01-16 2020-02-25 The Regents Of The University Of California Integrated intraoperative diagnosis and thermal therapy system
RU2593353C1 (en) 2015-02-19 2016-08-10 Алексей Николаевич Стеблюк Method for surgical treatment of pathological local defects of conjunctiva
US20180042867A1 (en) 2015-03-06 2018-02-15 Mitchell Woods Pharmaceuticals, Inc. Methods of treating cancer
BR112017019266B1 (en) 2015-03-10 2022-05-10 Bayer Animal Health Gmbh Pyrazolyl derivative compounds and pharmaceutical composition comprising said compound
WO2016145452A1 (en) 2015-03-12 2016-09-15 Myoscience, Inc. Methods and systems for preventing neuroma formations
CN108024803B (en) 2015-04-10 2021-10-19 安吉戴尼克公司 System and method for irreversible electroporation using thermally controlled electrodes
US20160377639A1 (en) 2015-06-27 2016-12-29 William Beaumont Hospital Methods for detecting, diagnosing and treating traumatic brain injury
WO2017042625A2 (en) 2015-09-09 2017-03-16 Genomedx Biosciences, Inc. Molecular subtyping, prognosis and treatment of prostate cancer
US20180271808A1 (en) 2015-10-01 2018-09-27 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
WO2017072768A2 (en) 2015-10-28 2017-05-04 Tpm Medical Systems Ltd. Systems and methods for locating and optionally treating nerve fibers
RU2768186C2 (en) 2015-12-11 2022-03-23 Рупрехт-Карлс-Университет Гейдельберг Combined drugs containing pkm2 and hmgb1 modulators
CN205449539U (en) 2016-02-19 2016-08-10 南方医科大学南方医院 Frozen section operation panel of drawing materials
CN108712884A (en) 2016-02-23 2018-10-26 日东电工株式会社 Identification piece
CN205885516U (en) 2016-04-25 2017-01-18 广州市瑞思美容设备有限公司 Freeze and dissolve fat equipment
US10682297B2 (en) 2016-05-10 2020-06-16 Zeltiq Aesthetics, Inc. Liposomes, emulsions, and methods for cryotherapy
US10555831B2 (en) 2016-05-10 2020-02-11 Zeltiq Aesthetics, Inc. Hydrogel substances and methods of cryotherapy
US11382790B2 (en) 2016-05-10 2022-07-12 Zeltiq Aesthetics, Inc. Skin freezing systems for treating acne and skin conditions
US20170326346A1 (en) 2016-05-10 2017-11-16 Zeltiq Aesthetics, Inc. Permeation enhancers and methods of cryotherapy
EP4349396A2 (en) 2016-05-13 2024-04-10 Pacira CryoTech, Inc. Systems for locating and treating with cold therapy
WO2018005964A1 (en) 2016-07-01 2018-01-04 Wake Forest University Health Sciences Modified carbohydrates, compositions comprising the same, and methods of making and using the same
JP6305468B2 (en) 2016-07-06 2018-04-04 株式会社ニトムズ Adhesive cleaner
WO2018044825A1 (en) 2016-08-30 2018-03-08 The General Hospital Corporation Cryotherapy and cryoablation systems and methods for treatment of tissue
GB201618291D0 (en) 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
JP6682037B2 (en) 2017-03-07 2020-04-15 旭化成株式会社 Polyasparatic coating composition, coating film, and coated article
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US20180263677A1 (en) 2017-03-16 2018-09-20 Zeltiq Aesthetics, Inc. Adhesive liners for cryotherapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
JP2018115314A (en) 2017-12-21 2018-07-26 小林 正則 Tape for prevention of lid droop

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946460A (en) * 1989-04-26 1990-08-07 Cryo Instruments, Inc. Apparatus for cryosurgery
US6032675A (en) * 1997-03-17 2000-03-07 Rubinsky; Boris Freezing method for controlled removal of fatty tissue by liposuction
US7479139B2 (en) * 2002-01-04 2009-01-20 Galil Medical Ltd. Apparatus and method for protecting tissues during cryoablation
US20090118722A1 (en) * 2006-10-31 2009-05-07 Ebbers Edward A Method and apparatus for cooling subcutaneous lipid-rich cells or tissue
US10610280B1 (en) * 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022251813A1 (en) * 2021-05-24 2022-12-01 B2M Medical, Inc. Method and system of removing visceral fat

Also Published As

Publication number Publication date
US11844559B2 (en) 2023-12-19
US10610280B1 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
US11844559B2 (en) Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
Kaufman et al. Office-based ultrasound-guided cryoablation of breast fibroadenomas
AU2001268527B2 (en) Device for biopsy and treatment of breast tumors
Saliken et al. The evolution and state of modern technology for prostate cryosurgery
US20090118722A1 (en) Method and apparatus for cooling subcutaneous lipid-rich cells or tissue
US20060118127A1 (en) Tissue protective system and method for thermoablative therapies
JP2005503227A (en) Apparatus and method for cryosurgical treatment of breast tumors
JP2007527729A (en) Apparatus and method for protecting tissue during cryoablation
JP2009522037A5 (en)
AU2001268527A1 (en) Device for biopsy and treatment of breast tumors
Sherar et al. Interstitial microwave thermal therapy for prostate cancer
Weber et al. Cryoablation: history, mechanism of action, and guidance modalities
Govorov et al. Specifics of prostate cryoablation
Ramadhyani Cryoablation for the treatment of solid cancers and pain management
US20170086899A1 (en) Method for Cryoablating Invasive Breast Carcinoma
WO2003059247A2 (en) Apparatus and method for protecting the neurovascular bundle during cryosurgical treatment of the prostate
Lee, Jr et al. Hepatic cryosurgery via minilaparotomy in a porcine model: an alternative to open cryosurgery
EP3060149B1 (en) Trocar with a freezing probe
AU2022281453A1 (en) Method and system of removing visceral fat
WO2022183117A1 (en) Apparatus and method for marginal ablation in tissue cavity
Manyak The evolution of cryotherapy for localized prostate cancer
Rukstalis et al. Prostate Cryoablation: 10 Successful Localized Prostate Therapy Cancer for Clinically
Vira Percutaneous Cryoablation for Renal Tumors
da Silva et al. Free Articles HOWIDOIT
Patel et al. Image-Guided Cryoablation of the Prostate

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE